Overview of the biology and management of ductal carcinoma in situ of the breast

Cancer

Volumn 74, Issue 1 S, 1994, Pages 350-361

  Frykberg, Eric R ^a   Bland, Kirby I ^b  

^a UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

breast; breast cancer early; breast cancer in situ; ductal carcinoma in situ; noninvasive breast cancer

Indexed keywords

BREAST CARCINOMA; BREAST DUCT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL FEATURE; CONFERENCE PAPER; EXCISION; HUMAN; MULTIPLE CANCER; PARTIAL MASTECTOMY; PRIORITY JOURNAL; RECURRENCE RISK;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, INFILTRATING DUCT; FEMALE; HUMAN;

EID: 0028284658     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.2820741321     Document Type: Article

References (143)

1. Early recognition of cancer of the breast
2. The study of mammary carcinoma by mammography and whole organ sectioning
3. An orientation to the concept of minimal breast cancer
4. The developmental pathology of breast cancer
5. Anatomic markers of human premalignancy and risk of breast cancer
6. The detection and treatment of early breast cancer
7. Abnormal involution of the mammary gland with its treatment by operation
8. Border‐line breast tumors
9. Comedo‐carcinoma (or comedo‐adenoma) of the female breast
10. Carcinoma in situ contrasted with benign penetrating epithelium
11. Lobular carcinoma in situ: a rare form of mammary carcinoma
12. A histologic classification of carcinoma of the breast
13. Preinvasive intraductal carcinoma of the breast
14. Minimal breast cancer: a clinical appraisal
15. Prognosis and treatment in minimal breast cancer
16. Minimal breast cancer: advance or anachronism?
17. Lobular carcinoma in situ of the breast
18. Current concepts for management of early (in situ and occult invasive) breast carcinoma
19. In situ breast carcinoma
20. Ductal carcinoma in situ (intraductal carcinoma) of the breast
21. Ductal carcinoma in situ of the breast
22. Vexed surgeons, perplexed patients, and breast cancers which may not be cancer
23. Current concepts in the detection and treatment of the earliest of early breast cancers
24. Implications from SEER data on breast cancer management
25. Noninvasive breast carcinoma: results of a national survey by the American College of Surgeons
26. Lobular carcinoma in situ and intraductal carcinoma of the breast
27. Breast carcinoma in situ in 167 women—incidence, mode of presentation, therapy, and follow‐up
28. Intraductal carcinoma of the breast (1960–1969)
29. The clinical significance of pre‐invasive breast carcinoma
30. Intraductal carcinoma of the breast
31. Precancerous and cancerous breast lesions during lifetime and at autopsy: a study of 83 women
32. Male breast cancer: a clinicopathologic study of 97 cases
33. Intraductal carcinoma of the breast: a comparative study
34. Intraductal carcinoma: analysis of presentation, pathologic findings, and outcome of disease
35. Comedo carcinoma of the breast
36. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 6), I: intraductal carcinoma (DCIS)
37. Ductal carcinoma involving the lobule of the breast: a source of confusion with lobular carcinoma in situ
38. Epithelial alterations in extralobular ducts of breasts with lobular carcinoma
39. Ductal carcinoma in situ: pathology and treatment
40. Ductal carcinoma in situ
41. The impact of pathology on the biologic, diagnostic, prognostic, and therapeutic considerations in breast cancer
42. Intramammary calcifications without an associated mass in benign and malignant diseases
43. Pathology of malignant lesions: noninfiltrating (in situ) carcinoma
44. Heterogeneity of intraductal carcinoma of the breast
45. Nonpalpable in situ ductal carcinoma of the breast
46. DNA analysis of ductal carcinoma in situ of the breast: a comparison with histologic features
47. Radiation therapy for intraductal carcinoma: is it an equal alternative?
48. Surgical treatment of ductal carcinoma in situ of the breast. 10‐ to 20‐year follow‐up
49. Duct carcinoma in situ: relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short term treatment failures
50. Mammographically detected duct carcinoma in situ: frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence
51. Recurrence after lumpectomy for comedo‐type intraductal carcinoma of the breast
52. Treatment of ductal carcinoma in situ of the breast
53. What to do about mammographically detected ductal carcinoma in situ
54. Subclinical ductal carcinoma in situ of the breast: treatment by local excision and surveillance alone
55. Cell kinetics of histologic variants of in situ breast carcinoma
56. Immunohisto‐chemical demonstration of C‐erb B‐2 protein in mammary ductal carcinoma in situ
57. Importance of cellular DNA content in pre‐malignant breast disease and pre‐invasive carcinoma of the female breast
58. Chromosome analysis of in situ breast cancer
59. Treatment of intraductal breast cancer—noncomedo type
60. Estrogen receptors in ductal carcinoma in situ of the breast
61. Distribution of estrogen receptor in ductal carcinoma in situ of the breast
62. Assessment of significance of proportions of intraductal and infiltrating tumor growth in ductal carcinoma of the breast
63. Staging and treatment of clinically occult breast cancer
64. Breast carcinoma in situ
65. Intraductal carcinoma of the breast (208 cases): clinical factors influencing treatment choice
66. The impact of microinvasion on axillary node metastases and survival in patients with intraductal breast cancer
67. Ductal carcinoma in situ with microinvasion: a curable entity using surgery alone without need for adjuvant therapy
68. Ductal carcinoma in situ
69. Noninvasive breast carcinoma: frequency of unsuspected invasion and implications for treatment
70. Intraductal noninvasive breast cancer: a comparison of three local treatments
71. In situ intraduct carcinoma of the breast: a long‐term follow‐up study
72. Intraductal carcinoma: long‐term follow‐up after treatment by biopsy alone
73. Intraductal carcinoma of the breast: follow‐up after biopsy only
74. Ductal carcinoma in situ (DCIS): a revised concept
75. Carcinoma in situ of the breast
76. Residual tumor after biopsy for non‐palpable ductal carcinoma in situ of the breast
77. In situ carcinoma of the breast
78. Axillary lymphadenectomy for intraductal carcinoma of the breast
79. Intraductal “noninfiltrating” carcinoma of the breast
80. Significance and staging of nonpalpable carcinomas of the breast
81. Intraduct carcinoma of the breast [editorial]
82. A comparison of palpable and nonpalpable breast cancers
83. Breast carcinoma with multiple sites of origin
84. Pitfalls of local excision in the treatment of carcinoma of the breast
85. Clinically occult breast cancer: multicentricity and implications for treatment
86. The extent and distribution of cancer in breasts with palpable primary tumors
87. 1–2 breast carcinoma
88. On the concept of carcinoma in situ of the breast
89. Duct carcinoma in situ: 227 cases without microinvasion
90. Multicentricity in nonpalpable breast carcinoma and its implications for treatment
91. Radical surgery and conservative treatment of ductal carcinoma in situ of the breast
92. Multicentricity and bilaterality in invasive breast carcinoma
93. Breast carcinoma in situ: a retrospective review of 112 cases with a minimum 10 year follow‐up
94. Bilaterality of cancer of the breast
95. Survival in bilateral breast cancer
96. Selective biopsy of the opposite breast
97. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol No. 4), XI: bilateral breast cancer
98. Bilateral primary breast cancers: a prospective clinicopathologic study
99. Risk of subsequent contralateral breast carcinoma in a population of patients with in situ breast carcinoma
100. The pathology of invasive cancer: a syllabus derived from the findings of the National Surgical Adjuvant Breast Project (protocol 4)
101. The impact of mammography on breast biopsy
102. Limitations of mammography in the identification of noninfiltrating carcinoma of the breast
103. The changing mammogram: a primary indication for needle localization biopsy
104. Role of needle localization of nonpalpable breast lesions
105. An overview and critical analysis of breast cancer screening
106. Breast biopsy: changing patterns during a five‐year period
107. Specimen radiography: a mandatory adjunct to mammography
108. Fine needle aspiration cytology in lieu of open biopsy in management of primary breast cancer
109. Final diagnosis by fine‐needle aspiration biopsy for definitive operation in breast cancer
110. Stereotaxic needle localization and cytological diagnosis of occult breast lesions
111. Prospective evaluation of radiologically directed fine‐needle aspiration biopsy of nonpalpable breast lesions
112. Three year follow‐up of benign fine‐needle aspiration biopsies of the breast
113. In situ carcinomas of the female breast: incidence, clinical findings, and DBCG proposals for management
114. Coexistent lobular carcinoma in situ and intraductal carcinoma in a single lobular‐duct unit
115. Lobular carcinoma in situ of the female breast: short‐term results of a prospective nationwide study
116. Lobular carcinoma in situ of the breast with ductal involvement: frequency and possible influence on prognosis
117. Borderline epithelial lesions of the breast
118. Cytologic differentiation between proliferative and nonproliferative breast disease in mammographically guided fine‐needle aspirates
119. Image cytophotometric DNA analysis of atypical hyperplasias and intraductal carcinomas of the breast
120. In situ ductal carcinoma of the breast: implications of disease pattern and treatment
121. Appropriate timing for breast reconstruction
122. Treatment of intraductal carcinoma with limited surgery: long‐term follow‐up
123. Natural history of in situ breast cancer in a defined population
124. Follow‐up of two treatment modalities for ductal cancer in situ of the breast
125. Management of screen detected ductal carcinoma in situ of the female breast
126. Duct carcinoma in situ: predictors of local recurrence and progression in patients treated by surgery alone
127. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer
128. Radiation therapy for treatment of intraductal carcinoma of the breast
129. Conservation therapy for breast cancers other than infiltrating ductal carcinoma
130. Radiation therapy for ductal carcinoma in situ of the breast
131. Duct carcinoma‐in‐situ of the breast: does conservation surgery and radiotherapy provide acceptable local control [abstract]?
132. The role of limited surgery with irradiation in primary treatment of ductal in situ breast cancer
133. Results of treating ductal carcinoma in situ of the breast with conservative surgery and radiation therapy
134. Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast‐conserving surgery and definitive irradiation
135. The presence of an extensive intraductal component following a limited excision correlates with prominent residual disease in the remainder of the breast
136. Conservation treatment of early breast cancer: long‐term results and complications
137. Alternatives in the surgical management of in situ breast cancer: a meta‐analysis of outcome
138. The intraductal carcinoma of the breast
139. In situ ductal carcinoma of the breast—analysis of clinical presentation and outcome in 156 consecutive cases
140. Therapy of in situ cancer